Article Text

Download PDFPDF
EBN resources page

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

SIGN Apps for iPhone and iPad,

The SIGN app has recently been updated and now contains quick reference guides (QRGs) for:

  • SIGN 136 Management of chronic pain

  • SIGN 135 Management of epithelial ovarian cancer

  • SIGN 134 Treatment of primary breast cancer

  • SIGN 133 Management of hepatitis C

The SIGN app has also had a complete re-design and now features:

  • Optimisation for the latest operating systems

  • Re-designed for improved legibility

  • Send pdf button feature

  • Split screen feature (ipad)

Prevention of stroke in patients with atrial fibrillation: a guide for primary care

This guide summarises the current evidence available to support the management of atrial fibrillation in primary care. The guide was developed by Healthcare Improvement Scotland by collating existing recent advice and guidance, including evidence-based guidelines and consensus recommendations for practice in NHS Scotland.

SIGN 137: management of lung cancer

This guideline replaces SIGN 80. It covers all aspects of the management of patients with small-cell lung cancer and non-small cell lung cancer, and reflects the most recent evidence on diagnostic and staging investigations, surgery, radiotherapy and systemic anticancer therapy.

Cochrane Nursing Care Field Trials Register

The Cochrane Nursing Care Field Trials Register contains randomised controlled trials and other relevant trial reports. The studies considered relate to interventions that are considered to be integral to, or associated with, the delivery of nursing care and delivered across a wide range of specialties and settings.

Drug and Therapeutics Bulletin (DTB): September 2013—January 2014

Dapagliflozin (Forxiga) for type 2 diabetes?

Dapagliflozin belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria. It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control. The company’s advertising materials claim that dapagliflozin provides a ‘novel method of controlling excess glucose’ with ‘secondary benefit of weight …

View Full Text